Project Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK- 3475) versus placebo after complete…

Basic data

Title:
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK- 3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group
Duration:
04/12/2015 to 03/12/2018
Abstract / short description:
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK- 3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group
Keywords:
clinical trial
klinische Studie

Staff

Managers

Faculty of Medicine
University of Tübingen

Contact persons

Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Diagnostic and Interventional Radiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine
Help

will be deleted permanently. This cannot be undone.